Agilent Acquires Luxcel Biosciences

Agilent stock is up heading into the announcement that the company acquired Luxcel Biosciences. I think the stock has run up too far to be a good entry right now.

Agilent Technologies has acquired Luxcel Biosciences, a developer of real-time fluorescence plate-reader based from vitro cell assay kits. This acquisition expands Agilent's cell evaluation portfolio with the inclusion of easy-to-use assay kits which are compatible with industry standard plate-readers.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Cambrex Corporation Oversold and Rising Large Players Volume

Cambrex Corporation stock was oversold and then it reported an impressive earnings and revenue surprise.

Cambrex Corporation reported EPS of $0.55 versus the estimate of $0.48. Revenue also beat coming in at $112.60 million versus the $108.44 million estimate. Revenue was up 13.4% on a year-over-year basis.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.